The Diagnosis and Treatment of Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease...
Uložené v:
| Vydané v: | Deutsches Ärzteblatt international Ročník 117; číslo 29-30; s. 513 |
|---|---|
| Hlavný autor: | |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Germany
20.07.2020
|
| Predmet: | |
| ISSN: | 1866-0452, 1866-0452 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease are presented.
This review is based on pertinent publications retrieved by a selective search in PubMed for original articles and reviews, as well as on current position statements by the relevant specialty societies.
AMD is subdivided into early, intermediate, and late stages. The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field defects. The main risk factors are age, genetic predisposition, and nicotine consumption. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors.
More research is needed on the dry late form of AMD in particular, which is currently untreatable. The treatment of the exudative late form with VEGF inhibitors is labor-intensive and requires a close collaboration of the patient, the ophthalmologist, and the primary care physician. |
|---|---|
| AbstractList | Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease are presented.
This review is based on pertinent publications retrieved by a selective search in PubMed for original articles and reviews, as well as on current position statements by the relevant specialty societies.
AMD is subdivided into early, intermediate, and late stages. The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field defects. The main risk factors are age, genetic predisposition, and nicotine consumption. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors.
More research is needed on the dry late form of AMD in particular, which is currently untreatable. The treatment of the exudative late form with VEGF inhibitors is labor-intensive and requires a close collaboration of the patient, the ophthalmologist, and the primary care physician. Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease are presented.BACKGROUNDAge-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease are presented.This review is based on pertinent publications retrieved by a selective search in PubMed for original articles and reviews, as well as on current position statements by the relevant specialty societies.METHODSThis review is based on pertinent publications retrieved by a selective search in PubMed for original articles and reviews, as well as on current position statements by the relevant specialty societies.AMD is subdivided into early, intermediate, and late stages. The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field defects. The main risk factors are age, genetic predisposition, and nicotine consumption. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors.RESULTSAMD is subdivided into early, intermediate, and late stages. The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field defects. The main risk factors are age, genetic predisposition, and nicotine consumption. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors.More research is needed on the dry late form of AMD in particular, which is currently untreatable. The treatment of the exudative late form with VEGF inhibitors is labor-intensive and requires a close collaboration of the patient, the ophthalmologist, and the primary care physician.CONCLUSIONMore research is needed on the dry late form of AMD in particular, which is currently untreatable. The treatment of the exudative late form with VEGF inhibitors is labor-intensive and requires a close collaboration of the patient, the ophthalmologist, and the primary care physician. |
| Author | Stahl, Andreas |
| Author_xml | – sequence: 1 givenname: Andreas surname: Stahl fullname: Stahl, Andreas organization: Department of Ophthalmology, University Medicine Greifswald |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33087239$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNT8lOwzAUtFARXeADuCAfuaQ4z3Zqn1DVsklFSKico5fktQQlTrGdA3w9kSgSl5k5jGaZspHrHDF2mYq5BGlu0H9HKpo5CBBzoVN5wiapybJEKA2jf3rMpiF8CJGlFuQZG0spzAKknbDb7TvxdY1714U6cHQV33rC2JKLvNvx5Z6SV2owUsWfsewb9HxNe3LkMdadO2enO2wCXRx5xt7u77arx2Tz8vC0Wm6Sw1ATk9SANmRJVllZDCtS1EaAriyawg4IWAgFBsUiVZUuSYMGpazFrJB2YXcwY9e_uQffffYUYt7WoaSmQUddH3JQWmZGSaMG69XR2hctVfnB1y36r_zvNPwAAU5aTA |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3238/arztebl.2020.0513 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1866-0452 |
| ExternalDocumentID | 33087239 |
| Genre | Journal Article Review |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | 04C 2WC 36B 53G AAWTL ABIVO ADBBV ADOJX ADZJE AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BMSDO CGR CUY CVF DARCH DIK E3Z EBD EBS ECM ECT EIF EIHBH ESI HYE M~E NPM OK1 RPM 7X8 AAFWJ |
| ID | FETCH-LOGICAL-p239t-18258e9e3d6cb6191a58025d9a8b9d9a2ab0428a0714d5ce52524499a6b3979f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 205 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000587674800053&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1866-0452 |
| IngestDate | Thu Jul 10 22:58:50 EDT 2025 Thu Jan 02 22:57:40 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 29-30 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p239t-18258e9e3d6cb6191a58025d9a8b9d9a2ab0428a0714d5ce52524499a6b3979f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7588619 |
| PMID | 33087239 |
| PQID | 2453684384 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2453684384 pubmed_primary_33087239 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-20 |
| PublicationDateYYYYMMDD | 2020-07-20 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Deutsches Ärzteblatt international |
| PublicationTitleAlternate | Dtsch Arztebl Int |
| PublicationYear | 2020 |
| References | 33785125 - Dtsch Arztebl Int. 2021 Feb 5;118(5):69 |
| References_xml | – reference: 33785125 - Dtsch Arztebl Int. 2021 Feb 5;118(5):69 |
| SSID | ssj0061923 |
| Score | 2.5931978 |
| SecondaryResourceType | review_article |
| Snippet | Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 513 |
| SubjectTerms | Germany - epidemiology Humans Intravitreal Injections Macular Degeneration - diagnosis Macular Degeneration - epidemiology Macular Degeneration - therapy Risk Factors |
| Title | The Diagnosis and Treatment of Age-Related Macular Degeneration |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33087239 https://www.proquest.com/docview/2453684384 |
| Volume | 117 |
| WOSCitedRecordID | wos000587674800053&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDI6AIcSF92O8FCSuYVuStslpmhgTl007DGm3KmnSaZdurIMDvx477eCEhMQlt1aW7caf_bk2IQ_IxGU-ajOvnGISAgSzkYgZl1bmxuusY7KwbCIZjdR0qsd1wa2s2yo3d2K4qN0iwxp5i0t4hZJCye7yjeHWKGRX6xUa26QhAMqgVyfTbxYh5AaYcKkYsmaQo2I1BUSplll9rr1F7oG3H8Exxe8IM0SaweF_ZTwiBzXGpL3KKY7Jli9OyN6wZtFPSRd8g_arHrt5SU3h6GTTb04XOe3NPAtNct7RoQmNqrTvZ2FANdrxjLwOnidPL6xepMCWXOg1gxwiUl574eLMglY6JlKAdZw2ymo4ubGYOhn8mclFYDoeQdTX2sQWab-cn5OdYlH4S0ITAJA6yaRMHC4Q51rlgDgAxEivpe2IJrnfqCYFR0X2wRR-8V6mP8ppkotKv-mymqiRCpxLCKJe_eHpa7KPRsP6Km_fkEYOn6m_JbvZx3peru6CB8A5Gg-_ABkEuDU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Diagnosis+and+Treatment+of+Age-Related+Macular+Degeneration&rft.jtitle=Deutsches+%C3%84rzteblatt+international&rft.au=Stahl%2C+Andreas&rft.date=2020-07-20&rft.issn=1866-0452&rft.eissn=1866-0452&rft.volume=117&rft.issue=29-30&rft.spage=513&rft_id=info:doi/10.3238%2Farztebl.2020.0513&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1866-0452&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1866-0452&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1866-0452&client=summon |